Zithromax (Azithromycin)

What is Zithromax?

Zithromax (azithromycin) is a macrolide antibiotic with a broad spectrum of antibacterial activity and a distinct pharmacokinetic profile that allows single-dose or short-course treatment for several infections. It is authorised under product- and country-specific conditions and is listed on the WHO Model List of Essential Medicines.

Azithromycin is widely used for community-acquired respiratory infections (pneumonia, bronchitis), ear and sinus infections, and selected skin and soft-tissue infections. It is also well known for its single 1 g oral dose option for uncomplicated genital chlamydia in selected circumstances. Convenience alone does not justify routine treatment of undiagnosed non-gonococcal urethritis.

How does Zithromax work?

Azithromycin is an azalide (a subclass of macrolide) antibiotic that works by inhibiting bacterial protein synthesis:

• 50S ribosomal subunit binding: Azithromycin binds to the 50S ribosomal subunit of susceptible bacteria, the same target as other macrolides including erythromycin.
• Translocation inhibition: This binding prevents the translocation step of protein synthesis — the movement of the peptide chain from the A-site to the P-site of the ribosome — halting elongation of the growing protein chain.
• Bacteriostatic/bactericidal: Azithromycin is primarily bacteriostatic (inhibits growth) at standard concentrations but can be bactericidal against some organisms at higher concentrations.
• Intracellular accumulation: A particularly important feature of azithromycin is its remarkable ability to accumulate within cells, including phagocytic cells (macrophages, polymorphonuclear cells). This results in tissue concentrations 10–100 times higher than plasma concentrations, and intracellular concentrations that persist for days after dosing.

This intracellular accumulation explains two key clinical properties:

1. Efficacy against intracellular pathogens: Chlamydia trachomatis is an obligate intracellular pathogen — it lives and replicates inside host cells. Azithromycin’s high intracellular concentrations make it effective against this organism.
2. Single-dose efficacy: The prolonged intracellular half-life (tissue half-life of 2–4 days) means that therapeutic levels persist in tissues for 5–7 days after a single oral dose, providing ongoing antibacterial activity despite the drug having cleared from plasma.

Who is Zithromax for?

Common indications:

• Respiratory tract infections, community-acquired pneumonia: First-line for atypical pathogens; alternative for typical pathogens in penicillin-allergic patients
• Skin and soft-tissue infections: Especially when first-line agents are not appropriate
• Otitis media and acute sinusitis: Where macrolides are clinically indicated
• Chlamydia (Chlamydia trachomatis): 1 g single oral dose — a selected alternative treatment (current European guidelines favour doxycycline as the preferred first-line, particularly for rectal chlamydia)
• Non-gonococcal urethritis (NGU): 1 g single oral dose — not a routine first-line regimen for undiagnosed NGU; resistance and the causative organism must be assessed
• Mycoplasma genitalium: The older 500 mg on day 1 then 250 mg on days 2–5 regimen is not a general current recommendation; specialist, resistance-guided treatment is required
• Chancroid (Haemophilus ducreyi): 1 g single oral dose

Zithromax is NOT appropriate for:

• Gonorrhoea (do not use as monotherapy — resistance is widespread in Europe)
• Patients with known macrolide allergy
• Patients with QT prolongation or on QT-prolonging medicines
• Patients with significant liver disease (azithromycin is hepatically processed)

Dosage

The 1 g dose can be taken as four 250 mg tablets or two 500 mg tablets simultaneously. Food instructions depend on the formulation: tablets may be taken with or without food, but capsules must be separated from food according to their leaflet. Take with adequate water.

Side effects

Azithromycin is generally well tolerated, with a better gastrointestinal side effect profile than erythromycin.

Common side effects (affecting 1 to 10 in 100 people)

• Nausea
• Diarrhoea
• Abdominal pain
• Vomiting (less common than with erythromycin)
• Headache

Less common side effects

• Flatulence
• Dyspepsia
• Dizziness
• Elevated liver enzymes
• Skin rash

Clinically important side effects

QT prolongation: Azithromycin prolongs the QT interval and can increase the risk of cardiac arrhythmias, including potentially fatal ventricular arrhythmias (torsades de pointes). The EMA has issued guidance on this risk. Risk is higher in patients who:

• Have known QT prolongation or hypokalemia
• Are taking other QT-prolonging medicines
• Have bradycardia or arrhythmias
• Have significant cardiovascular disease

Severe allergic reactions: Including angioedema, anaphylaxis, and Stevens-Johnson syndrome (rare)

Clostridioides difficile-associated diarrhoea: As with all antibiotics, disruption of gut flora can predispose to C. difficile overgrowth.

Hepatotoxicity: Severe liver reactions including cholestatic jaundice have been reported rarely.

Zithromax vs alternative antibiotics for chlamydia

Current guideline position: The European STI guidelines (2015 and subsequent updates) and WHO guidelines both list azithromycin 1 g as a selected alternative treatment for uncomplicated genital chlamydia. More recent evidence and meta-analyses have favoured doxycycline as the preferred choice due to higher cure rates particularly for rectal chlamydia infection. Azithromycin remains the preferred single-dose option and may be more appropriate where adherence to a 7-day course is a concern.

Online assessment for Zithromax (Azithromycin)

Zithromax (azithromycin) is a prescription-only medicine (POM) in all EU member states. It cannot legally be dispensed without a valid prescription from a licensed medical professional.

Prescrivia operates as a technology intermediary: we do not prescribe medicines, employ doctors, or sell medicines. Our platform connects patients with independent doctors who can conduct confidential online health assessments.

Availability of an online assessment, prescribing, dispensing and delivery depends on the medicine, country and applicable law. Spain prohibits distance sale of prescription medicines; a catalogue entry or cross-border prescription does not establish a right to delivery. An in-person examination or testing may be required.

The process, where legally and clinically available:

1. Complete a health assessment: Describe your symptoms, any STI test results, relevant medical history, and any medications you take.
2. Doctor review: An independent doctor reviews your assessment. If azithromycin is clinically appropriate, they may issue a prescription.
3. Pharmacy fulfilment: The prescription is sent to a pharmacy partner to assess dispensing and any supply under the applicable country rules.

Important: Prescrivia does not guarantee that a prescription will be issued. All prescribing decisions are made independently by qualified medical professionals.

Important safety information

Do not take Zithromax if you:

• Are allergic to azithromycin or other macrolide antibiotics (e.g., erythromycin, clarithromycin)
• Have significant liver disease or hepatic dysfunction
• Are taking ergotamine or dihydroergotamine (risk of ergotism)

Tell your doctor before taking Zithromax if you:

• Have a history of QT prolongation or cardiac arrhythmias
• Have hypokalaemia or hypomagnesaemia (electrolyte imbalances increase QT risk)
• Are taking other QT-prolonging medicines (antiarrhythmics, antipsychotics, certain antibiotics)
• Are taking warfarin (azithromycin may increase anticoagulant effect — INR monitoring advised)
• Are taking antacids containing aluminium or magnesium (take azithromycin at least 1 hour before or 2 hours after)
• Are pregnant or breastfeeding

Partner notification: If diagnosed with chlamydia or another STI, sexual partners from the preceding 6 months should be notified and offered testing and treatment to prevent reinfection and further transmission.

Sources

• Product information / clinical reference 1
• Product information / clinical reference 2
• Product information / clinical reference 3

Medical information on this page is based on the following sources:

• World Health Organization (WHO). WHO Guidelines for the Treatment of Chlamydia trachomatis. 2016. who.int
• World Health Organization (WHO). WHO Model List of Essential Medicines. 22nd edition, 2021.
• European STI Guidelines Editorial Board. 2015 European guideline on the management of Chlamydia trachomatis infections. Journal of the European Academy of Dermatology and Venereology.

The content-edit date does not certify a clinical review. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.